MDACC Study No:2010-0296 ( NCT No: NCT01262027)
Title:A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients with Stage IV HER2-negative IBC and Local or Distant Relapse
Principal Investigator:Vicente Valero
Treatment Agent:TKI258
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if dovitinib can help to
control inflammatory breast cancer. The safety of this drug will also be
Hide details for General InformationGeneral Information

Disease Group:Breast
Phase of Study:Phase II
Treatment Agents:TKI258
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Vicente Valero
Dept:Breast Medical Oncology
For Clinical Trial Enrollment:713-563-3735
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults